Back to Feed
ClinicalTrials.gov|Clinical Trial
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Canadian Cancer Trials Group
Abstract
The purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma. Phase: PHASE2 Status: NOT_YET_RECRUITING Conditions: Mantle Cell Lymphoma Interventions: Zanubrutinib; Sonrotoclax; CAR-T Cell Therapy
Keywords
Mantle Cell Lymphoma